BiotechTV
SITC 2024: Aulos Bioscience CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company’s IL-2 redirecting antibody
November 9, 2024
CEO Aron Knickerbocker and BiotechTV’s Brad Loncar review AU-007 safety and efficacy data presented at SITC, including a correlation between Treg reduction and longer progression-free survival.
Rx for Biotech
Unlocking the Power of IL-2 with Aulos CEO, Aron Knickerbocker
September 18, 2024
In this Rx for Biotech episode, CEO Aron Knickerbocker and Christopher Leidli discuss lessons learned as a biotech CEO and how AU-007 differentiates itself from other IL-2 products in development.
The Business of Biotech
First AI Antibody In Humans with Aulos’ Aron Knickerbocker
July 15, 2024
CEO Aron Knickerbocker and Matt Pillar engage in a lively discussion about how data drives decision-making at Aulos and the role AI has played in the company’s innovative IL-2 antibody.
Life Science Success
Revolutionizing Cancer Treatment with Aron Knickerbocker of Aulos
May 18, 2024
In this conversation with Life Science Success, CEO Aron Knickerbocker discusses Aulos’ innovative approach to solid tumor cancers and shares insights on the future of oncology.
BiotechTV
Aulos Bioscience CEO Aron Knickerbocker discusses his company’s antibody approach to IL-2 at #ASCO24
June 2, 2024
CEO Aron Knickerbocker joins BiotechTV’s Brad Loncar to discuss the benefits of focusing on the CD25 binding portion of IL-2 as well as the data presented at ASCO.
Clinical Trials Arena
Aulos to begin Phase II portion of solid tumour therapy trial
December 19, 2023
With Aulos announcing the Phase 2 portion of its Phase 1/2 study of AU-007, Clinical Trials Arena summarizes AU-007 developments to date and notes what’s ahead with the Phase 2 expansion cohorts.
The Bio Report
Realizing the Promise of IL-2 Therapies with AI
December 13, 2023
CEO Aron Knickerbocker joins biotech insider Daniel Levine for an in-depth discussion on the potential for IL-2 therapies in solid tumors, how AU-007 differs from other drugs in the class and its AI-based design.
Targeted Oncology
Early Antitumor Activity and Safety Seen With AU-007 Across Solid Tumors
November 10, 2023
Targeted Oncology reports on AU-007 Phase 1 data presented at the 38th SITC Annual Meeting, with the drug showing early evidence of antitumor activity when given alone or in combination with aldesleukin.
BioWorld
Aulos Bioscience raises $20 million in series A to further alternative IL-2 approach
August 21, 2023 | PDF 49KB
CEO Aron Knickerbocker speaks with BioWorld about the company’s $20 million Series A extension funding, the science behind AU-007 and the latest on its Phase 1/2 clinical study in solid tumor cancers.
Life Science Leader
Leading Aulos Bioscience’s “Triumvirate” Model
June 1, 2023
During an interview with Life Science Leader, CEO Aron Knickerbocker discusses Aulos’ commitment to maximizing the ingenuity of a balanced team and continuing development of AU-007, the company’s lead candidate.
Nature Biotechnology
IL-2 upgrades show promise at ASCO
July 13, 2022
Nature Biotechnology looks at IL-2 therapeutics, including AU-007 and its unique ability to bind to IL-2, blocking activation of trimeric receptors on Tregs and endothelial cells while stimulating effector T cells and NK cells.